SAN DIEGO, March 10, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) reported today that Genmab A/S
announced plans for a Phase 1 clinical trial of a subcutaneous
formulation of the anti-CD38 antibody daratumumab using the
ENHANZE™ technology. In December
2014, Janssen Biotech, Inc. (Janssen) entered into an
agreement with Halozyme Therapeutics for the purpose of developing
and commercializing products combining proprietary Janssen
compounds with Halozyme's ENHANZE technology. This agreement has
the potential to lead to the development of a subcutaneous
formulation of daratumumab. Daratumumab is being developed under a
collaboration between Janssen and Genmab A/S since August 2012 when Genmab granted Janssen an
exclusive worldwide license to develop, manufacture, and
commercialize daratumumab.
About Daratumumab
Daratumumab, a human monoclonal antibody that targets CD38 on
the surface of multiple myeloma cells, is in clinical development
as a single agent and in combination with standard of care
therapies in several settings of multiple myeloma. Daratumumab may
also have potential in other hematologic malignancies in which CD38
is expressed, including non-Hodgkins lymphoma and various
leukemias.
About ENHANZE™
ENHANZE™ is Halozyme's proprietary drug delivery platform based
on the Company's patented recombinant human hyaluronidase enzyme
(rHuPH20). rHuPH20 has been shown to remove traditional limitations
on the volume of biologics that can be delivered subcutaneously
(just under the skin). By using rHuPH20, some biologics and
compounds that are administered intravenously may instead be
delivered subcutaneously. This delivery has been shown in studies
to reduce health care practitioner time required for administration
and shorten time for drug administration. ENHANZE may also benefit
subcutaneous biologics by reducing the need for multiple
injections.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program,
our investigational drug PEGPH20, applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor. PEGPH20
is currently in development for metastatic pancreatic cancer and
non-small cell lung cancer and has potential across additional
cancers in combination with different types of cancer therapies. In
addition to its proprietary product portfolio, Halozyme has
established value-driving partnerships with leading pharmaceutical
companies including Roche, Pfizer, Janssen and Baxter for its drug delivery platform,
ENHANZE™, which enables biologics and small molecule compounds that
are currently administered intravenously to be delivered
subcutaneously. Halozyme is headquartered in San Diego, CA. For more information on how we
are innovating, please visit our corporate website at
www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements (including, without
limitation, statements concerning the development and
commercialization of product candidates (including those under the
Halozyme-Janssen collaboration), the potential benefits and
attributes of such product candidates) that involve risk and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. The forward-looking
statements are also identified through use of the words "believe,"
"enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar
meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including unexpected results or delays in
development and regulatory review, regulatory approval
requirements, unexpected adverse events, competitive conditions and
the continuation of the Halozyme-Janssen and other collaborations.
These and other factors that may result in differences are
discussed in greater detail in the Company's Annual Report on Form
10-K filed with the Securities and Exchange Commission on
March 2, 2015.
Investor/Media Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-reports-selection-of-first-product-candidate-under-janssen-collaboration-300047864.html
SOURCE Halozyme Therapeutics, Inc.